Lanean...
Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies
Venetoclax (ABT-199) is a Bcl-2-specific BH3-mimetic that has shown significant promise in certain subtypes of CLL as well as in several other hematologic malignancies. As in the case of essentially all targeted agents, intrinsic or acquired resistance to this agent generally occurs, prompting the s...
Gorde:
| Argitaratua izan da: | Leuk Lymphoma |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5826810/ https://ncbi.nlm.nih.gov/pubmed/28838268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1366999 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|